Table II.
Treatment | EAE/Totalb | Onsetc | Maximum Scored | Cumulative Scoree |
---|---|---|---|---|
PBS | 5/5 | 8.4 ± 9.5 | 5 | 58.8 |
H69f | 5/5 | 12.2 ± 4.0 | 3 | 14.6* |
H647f | 5/5 | 9.6 ± 0.9 | 5 | 27.9† |
H696 CD25+CD4+ T cellsg | 3/5 | 19.0 ± 5.7*,* | 1 | 1.6*,* |
H696 CD25−CD4+ T cellsg | 5/5 | 11.6 ± 0.5* | 5 | 25.2* |
H647 CD25+CD4+ T cellsg | 5/5 | 12.1 ± 0.7† | 3 | 15.4†,† |
H647 CD25−CD4+ T cellsg | 5/5 | 9.8 ± 0.8 | 3 | 48.2 |
Naive CD25+CD4+ T cellsg | 5/5 | 12.8 ± 0.4* | 5 | 40.2* |
Naive CD25−CD4+ T cellsg | 5/5 | 9.2 ± 0.4 | 5 | 43.0* |
SJL/J mice were challenged as per Table I.
Number of mice with clinical EAE per group.
Mean day onset ± SEM of clinical disease. *, p < 0.001 for PBS vs H696 CD25+CD4+ T cells, PBS vs H696 CD25−CD4+ T cells, and H696 vs H696 CD25+CD4+ T cells. †, p < 0.001 for PBS vs H647.
Maximum daily clinical score.
Cumulative clinical scores were calculated as the sum of all clinical scores from disease onset to day 25 postchallenge and divided by the number of mice in each group. *, p < 0.001 for PBS vs H696, PBS vs H696 CD25+CD4+ T cells, PBS vs H696 CD25−CD4+ T cells, and H696 vs H696 CD25+CD4+ T cells. †, p < 0.001 for PBS vs H647, PBS vs H647 CD25+CD4+ T cells, and H647 vs H647 CD25+CD4+ T cells.
Mice were vaccinated 7 days before challenge with 5 × 109 CFU of S. Typhimurium H696 or S. Typhimurium H647.
CD25−CD24+ T cells or CD25+CD4+ T cells from SJL/J mice previously immunized with H696 or H647 or from naive SJL/J mice were injected i.v 1 day before the induction of EAE with PLP139–151.